Therapeutic use of LNG intrauterine system (Mirena) for menorrhagia due to benign lesions – An alternative to hysterectomy ?

نویسنده

  • Kumar Sushil
چکیده

METHOD(S) : This was a prospective, non-comparative study. Twenty patients who had menorrhagia due to non-malignant causes were included in the study (age range 20-42 years). However patients of fibroid uterus with uterine size more than 12 weeks and those with submucous fibroid were excluded. A LNG-releasing-intrauterine system was inserted on any day during bleeding or within a week of cessation of bleeding. Menstrual blood loss was assessed, before LNG-IUS was inserted, and after 3, 6, and 12 months of use.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Levonorgestrel Intrauterine System (lng-ius, Mirena) in Dysfunctional Uterine Bleeding (dub)

Objectives: To determine progress of women presenting with dysfunctional uterine bleeding (i.e decrease in amount and duration of bleeding in days) due to a cause amenable to treatment. To evaluate improvement in Haemoglobin level (Hb gm%) in patients during treatment. Material and Methods: The study was conducted in the Department of Gynecology & Obstetrics, Khyber Teaching Hospital, Peshawar,...

متن کامل

Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)--a systematic enquiry and overview.

Levonorgestrel releasing-intrauterine systems (LNG-IUS) were originally developed as a method of contraception in the mid 1970s. The only LNG-IUS approved for general public use is the Mirena LNG-IUS, which releases 20 mcg of levonorgestrel per day directly in to the uterine cavity. However, new lower dose (10 and 14 mcg per day) and smaller sized LNG-IUS (MLS, FibroPlant-LNG) are currently und...

متن کامل

Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up.

CONTEXT Because menorrhagia is often a reason for seeking medical attention, it is important to consider outcomes and costs associated with alternative treatment modalities. Both the levonorgestrel-releasing intrauterine system (LNG-IUS) and hysterectomy have proven effective for treatment of menorrhagia but there are no long-term comparative studies measuring cost and quality of life. OBJECT...

متن کامل

The Role of Mirena (Intra-uterine progestogens), Other than Contraceptive benefits: Current Concepts and Practices

Mirena is a long acting intrauterine hormone-releasing (LNG-IUS) contraceptive system with a flexible plastic T-shaped frame bearing a levonorgestrel(LNG)containing cylinder which releases small doses levonorgestrel into the uterine cavity after insertion with maximum effect on the endometrium and minimum progestogenic side-effect. LNG causes thinning of the endometrium, atrophy of the endometr...

متن کامل

Endometrial adenocarcinoma in association with a levonorgestrel-releasing intrauterine system (Mirena).

The levonorgestrel-releasing intrauterine system (LNGIUS), Mirena®, has been licensed as a contraceptive in the UK since 1995. In 2002, Mirena became licensed also for the management of idiopathic menorrhagia and in 2004 the product licence was extended further to use for “endometrial protection” to prevent endometrial hyperplasia in women receiving oestrogen replacement therapy. We report a ca...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2006